問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of Nuclear Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

蒲永孝Pu, Yeong-Shiau
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • uroassistant2014@gmail.com

Recruiting Trial

70Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蒲永孝

List

147Cases

2020-12-01 - 2022-03-22

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2022-12-20

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2025-10-31

Phase I

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    AMG 509

Participate Sites
2Sites

Recruiting2Sites

2021-11-01 - 2022-08-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-08-01 - 2026-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2015-11-01 - 2026-12-31

Phase III

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

  • Condition/Disease

    Prostate Cancer

  • Test Drug

    Enzalutamide (formerly MDV3100)

Participate Sites
9Sites

Terminated7Sites

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2008-10-31 - 2010-06-15

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-11-15 - 2011-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-06-15 - 2021-06-30

Phase III

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    enfortumab vedotin

Participate Sites
6Sites

Recruiting5Sites

Study ended1Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2021-06-01 - 2022-05-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 11 12 13 14 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB